Stocktoria

ICU MEDICAL INC/DE ICUI

Nasdaq · stock · Surgical & Medical Instruments & Apparatus · website · IPO 1992-03-31

ICU MEDICAL INC/DE (ICUI) earns a Piotroski F-score of 6/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $2.2B at a 0.0% net margin.

Chart by TradingView
53/100
Stocktoria Quality Score · grade C
6/9
Piotroski F — financial health
2.9
Altman Z″ — distress risk · safe
Dividend yield · no dividend
-2.69
Beneish M-score — earnings quality · low

Quality score trend · recomputed for each fiscal year

Piotroski F /9
6 4 5 5 4 6 1 6 5 6 2016201720182019202020212022202320242025

Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.

$179.34 as of 2026-08-01 · +40.5% 1y
$119.20$179.3452-wk

Beneish M-score: -2.69 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.

Market cap USD$3.7B
Net margin 5y avg-0.3%
Return on equity 5y avg-0.9%
Beta0.78
Employees13,000

Analyst price target

$172.50 -3.8% vs last
consensus: strong buy · 8 analysts
target range $160.00 – $200.00 · median $167.50
4 strong buy · 4 buy ·
Recent analyst actions
DateFirmRating
2026-06-15BTIGBuy (init)
2026-05-27NeedhamBuy (up)
2026-04-27KeybancOverweight (main)
2026-04-17Piper SandlerOverweight (main)
2026-02-20KeybancOverweight (main)
2026-02-20Piper SandlerOverweight (main)

Wall Street analyst consensus — a sentiment gauge, not our scoring.

Smart money · insiders, last 12 months

Insiders net sold -$882,242 on the open market · 3 trades

Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.

Revenue trend · last 10y · up

How it ranks in Manufacturing · percentile among 1957 companies

Piotroski Fstronger than 78%
Net marginstronger than 54%
Return on equitystronger than 58%
Revenue growthstronger than 19%

Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.

Piotroski F breakdown · 6/9 tests passed

Altman Z″ components · safe zone

ComponentValue
Working capital / assets0.171
Retained earnings / assets0.171
EBIT / assets0.011
Equity / liabilities1.102

Sector peers · similar-size Manufacturing companies compare side by side →

TickerCompanyPiotroski FAltman Z″P / ERevenue growth
ICUIICU MEDICAL INC/DE6/92.9-6.3%
TFXTELEFLEX INC5/93.56+17.2%
PODDINSULET CORP6/94.7844.4+30.7%
IARTINTEGRA LIFESCIENCES HOLDINGS CORP5/91.17+1.5%
GMEDGLOBUS MEDICAL INC7/910.0621.8+16.7%
MMSIMERIT MEDICAL SYSTEMS INC7/94.9333.3+11.8%
PENPenumbra Inc6/98.5970.1+17.5%

All Manufacturing companies →

About ICU MEDICAL INC/DE

ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications worldwide. It offers Clave needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoLock closed system transfer devices and ChemoClaveTM for preparation and administration of hazardous drugs; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; ClearGuard, SwabCap, and SwabTip disinfection caps; and vascular access products. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride, sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, such as outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.

FAQ

Is ICUI financially healthy?

ICU MEDICAL INC/DE's Piotroski F-score is 6/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.

Does ICUI pay a dividend?

No, ICU MEDICAL INC/DE does not currently pay a dividend.

How profitable is ICUI?

In FY2025, ICU MEDICAL INC/DE had a net margin of 0.0% and a return on equity of 0.0%.

Is ICUI overvalued or undervalued?

ICU MEDICAL INC/DE trades at about 5978.0× trailing earnings — above its 10-year norm (10-year range 24.3×–4996.7×, median 49.8×). Stocktoria reports the data, not buy/sell advice.

What is the analyst price target for ICUI?

The average Wall-Street price target for ICU MEDICAL INC/DE is $172.50, about 3.8% below the recent price, from 8 analysts (consensus: strong buy).

Is ICUI a good stock to buy?

Stocktoria doesn't give buy or sell advice, but here is the data on ICU MEDICAL INC/DE: a Piotroski F-score of 6/9, an Altman Z″ in the safe zone. Weigh these quality and valuation signals against your own goals.

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.